{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:13:13Z","timestamp":1778897593544,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103291","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:24:39Z","timestamp":1765297479000},"page":"103291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antithrombotic therapy in lower extremity peripheral artery disease patients with venous thromboembolism: a nationwide cohort study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9571-7431","authenticated-orcid":false,"given":"Jamilla","family":"Goedegebuur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1664-3721","authenticated-orcid":false,"given":"Elena","family":"Butera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-0007","authenticated-orcid":false,"given":"Qingui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-879X","authenticated-orcid":false,"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-8879","authenticated-orcid":false,"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-2931","authenticated-orcid":false,"given":"Roberto","family":"Pola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-2892","authenticated-orcid":false,"given":"Angelo","family":"Porfidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2618-347X","authenticated-orcid":false,"given":"Stefano","family":"Barco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6520-1597","authenticated-orcid":false,"given":"Thijs E.","family":"van Mens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0669-4272","authenticated-orcid":false,"given":"Joost R.","family":"van der Vorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-2303","authenticated-orcid":false,"given":"Suzanne C.","family":"Cannegieter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9961-0754","authenticated-orcid":false,"given":"Frederikus A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103291_bib1","doi-asserted-by":"crossref","first-page":"e1553","DOI":"10.1016\/S2214-109X(23)00355-8","article-title":"Global burden of peripheral artery disease and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"11","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.rpth.2025.103291_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1024\/0301-1526\/a001029","article-title":"Peripheral artery disease and the risk of venous thromboembolism","volume":"51","author":"Sykora","year":"2022","journal-title":"Vasa"},{"key":"10.1016\/j.rpth.2025.103291_bib3","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1055\/s-0031-1297367","article-title":"Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective","volume":"37","author":"Lijfering","year":"2011","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.103291_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-9560-2-12","article-title":"Blood coagulation and the risk of atherothrombosis: a complex relationship","volume":"2","author":"Spronk","year":"2004","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2025.103291_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11739-019-02238-6","article-title":"Is there a link between venous and arterial thrombosis? A reappraisal","volume":"15","author":"Prandoni","year":"2020","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.rpth.2025.103291_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2021.06.012","article-title":"Relations of arterial stiffness and endothelial dysfunction with incident venous thromboembolism","volume":"204","author":"Ko","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103291_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fcvm.2019.00033","article-title":"Searching for a common thrombo-inflammatory basis in patients with deep vein thrombosis or peripheral artery disease","volume":"6","author":"Kremers","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"23 Suppl 1","key":"10.1016\/j.rpth.2025.103291_bib8","first-page":"I9","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103291_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular risk factors associated with venous thromboembolism","volume":"4","author":"Gregson","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rpth.2025.103291_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.107.709204","article-title":"Cardiovascular risk factors and venous thromboembolism: a meta-analysis","volume":"117","author":"Ageno","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103291_bib11","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2024.12.030","article-title":"Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease: meta-analysis of randomized trials","volume":"85","author":"Rashedi","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2025.103291_bib12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rpth.2025.103291_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.avsg.2021.02.025","article-title":"Incidence of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization","volume":"75","author":"Desai","year":"2021","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.rpth.2025.103291_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.15580","article-title":"Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization","volume":"5","author":"Hess","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2025.103291_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.avsg.2023.12.092","article-title":"Comparative outcomes of peripheral vascular interventions in patients on chronic anticoagulation with factor Xa inhibitors and vitamin K antagonists","volume":"104","author":"Huttler","year":"2024","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.rpth.2025.103291_bib16","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2025.103291_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM198601303140505","article-title":"Variations in the use of medical and surgical services by the Medicare population","volume":"314","author":"Chassin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103291_bib18","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood.2023021638","article-title":"How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?","volume":"143","author":"May","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103291_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9973","article-title":"Time trends in patient characteristics, anticoagulation treatment, and prognosis of incident nonvalvular atrial fibrillation in the Netherlands","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2025.103291_bib20","series-title":"Initial treatment of acute venous thromboembolism","year":"2016"},{"key":"10.1016\/j.rpth.2025.103291_bib21","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.rpth.2025.103291_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103291_bib23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.amjmed.2019.04.043","article-title":"Peripheral artery disease: past, present, and future","volume":"132","author":"Campia","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2025.103291_bib24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1186\/s12916-024-03792-3","article-title":"Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial fibrillation: analysis from two prospective observational registries","volume":"22","author":"Mei","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.rpth.2025.103291_bib25","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103291_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/hematology.2020000151","article-title":"Combining antiplatelet and anticoagulant therapy in cardiovascular disease","volume":"2020","author":"Barnes","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2025.103291_bib27","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103291_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.atherosclerosis.2019.09.012","article-title":"Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review","volume":"293","author":"Agnelli","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.rpth.2025.103291_bib29","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","article-title":"Mortality with paclitaxel-coated devices in peripheral artery disease","volume":"383","author":"Nordanstig","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103291_bib30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103291_bib31","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejvs.2021.10.026","article-title":"Revascularisation for symptomatic peripheral artery disease: external applicability of the VOYAGER PAD trial","volume":"63","author":"S\u00f8gaard","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.rpth.2025.103291_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ehjcvp\/pvy027","article-title":"Critical appraisal of the COMPASS trial","volume":"4","author":"Niessner","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.rpth.2025.103291_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ejvs.2021.01.020","article-title":"The Voyager PAD trial in a surgical perspective: a debate","volume":"61","author":"Vahl","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.rpth.2025.103291_bib34","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(25)00449-0","article-title":"Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial","volume":"405","author":"Choi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103291_bib35","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103291_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1001\/jamacardio.2018.4171","article-title":"Incidence, characteristics, and outcomes of myocardial infarction in patients with peripheral artery disease: insights from the EUCLID trial","volume":"4","author":"Olivier","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.rpth.2025.103291_bib37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103291_bib38","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1161\/CIRCULATIONAHA.122.059405","article-title":"Rivaroxaban 2.5 mg twice daily plus aspirin reduces venous thromboembolism in patients with chronic atherosclerosis","volume":"145","author":"Pogosova","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103291_bib39","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.rpth.2025.103291_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109414","article-title":"Antithrombotic therapy for lower limb peripheral arterial disease: a deep dive into guideline quality and recommendation diversity","volume":"253","author":"Li","year":"2025","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2025.103291_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.994085","article-title":"Adherence and persistence to oral anticoagulants in patients with atrial fibrillation: a Belgian nationwide cohort study","volume":"9","author":"Grymonprez","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.rpth.2025.103291_bib42","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1055\/a-2161-0928","article-title":"Prevalence and predictors of nonadherence to direct oral anticoagulant treatment in patients with atrial fibrillation","volume":"7","author":"van der Horst","year":"2023","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2025.103291_bib43","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.rpth.2025.103291_bib44","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1093\/eurheartj\/ehab421","article-title":"Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study","volume":"42","author":"Toorop","year":"2021","journal-title":"Eur Heart J"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:52:53Z","timestamp":1778896373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925006156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925006156"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103291","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic therapy in lower extremity peripheral artery disease patients with venous thromboembolism: a nationwide cohort study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103291"}}